TP53 hotspot in MCL — chemoimmuno failure predictor; acalabrutinib-based 1L preferred. Ho...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-TP53-R273H-MCL |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-MCL |
| Sources | SRC-CIVIC SRC-ESMO-MCL-2024 SRC-NCCN-BCELL-2025 |
Actionability Facts
| Biomarker | BIO-TP53-MUTATION |
|---|---|
| Variant | R273H |
| Disease | DIS-MCL |
| ESCAT tier | IIA |
| Recommended combinations | acalabrutinib + rituximab, brexu-cel |
| Evidence summary | TP53 hotspot in MCL — chemoimmuno failure predictor; acalabrutinib-based 1L preferred. Hotspot R273H is among the most frequent DBD missense — gain-of-function dominant-negative behavior in some functional assays. |
Notes
ESCAT IIA. Hotspot R273H listed under BIO-TP53-MUTATION (gene-level BIO; no per-hotspot BIO entity).
Used By
No reverse references found in the YAML corpus.